

## Qualifying Children Age 8-19 Months Entering Their Second RSV Season<sup>1</sup>

| Group <sup>2</sup>                                                                                                                                            | Clinical Requirement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Preterm &lt; 32 weeks 0 days gestation*</b>                                                                                                                | Regardless of need for medication.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Chronic lung disease (CLD) or other significant neonatal conditions*</b><br>requiring ongoing medical intervention in the 6 months prior to the RSV season | CLD attributable to prematurity or to other significant neonatal conditions (e.g., meconium aspiration or congenital diaphragmatic hernia) who required medical support (e.g., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) at any time during the 6-month period before the start of the second RSV season. <i>See below for CF.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Hemodynamically significant congenital heart disease (CHD)*</b>                                                                                            | <p>Infants with acyanotic heart disease who are receiving medication to control congestive heart failure and/or will require cardiac surgical procedures. Infants with moderate to severe pulmonary hypertension. Infants with cyanotic CHD (e.g., single ventricle) with cardiologist recommendation.</p> <p><b>Not recommended unless other qualifying conditions:</b></p> <ul style="list-style-type: none"> <li>• Hemodynamically insignificant CHD (e.g., secundum ASD, small VSD, pulmonic stenosis, mild aortic stenosis, mild coarctation of the aorta, and small PDA)</li> <li>• Lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure</li> <li>• Infants with mild cardiomyopathy who are not receiving medical therapy for the condition</li> </ul> |
| <b>Anatomic pulmonary abnormality or neuromuscular disorder*</b><br>that increases the risk of severe RSV disease                                             | <ul style="list-style-type: none"> <li>• Clinically significant anatomic pulmonary or airway abnormality that impairs ventilation or clearance of respiratory secretions and increases the risk of severe RSV disease.</li> <li>• Neuromuscular disorders include any neurologic condition, sequelae of HIE at birth, TBI, chromosomal abnormalities, metabolic disorders with neuro/muscular involvement, cerebral and other degenerative CNS diseases, muscular dystrophies, neural tube defects, motor neuron diseases, epilepsy and recurrent seizures.</li> </ul>                                                                                                                                                                                                                                                    |
| <b>Severe immunocompromise</b>                                                                                                                                | Includes, but is not limited to, children who have received hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT), have a primary immunodeficiency, or are undergoing chemotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Trisomy 21 or other chromosomal differences*</b><br>associated with increased risk of severe RSV disease                                                   | Data are limited to Trisomy 21, but children with other trisomies or chromosomal differences that predispose them to higher risk of RSV disease (e.g., problems with airway clearance, immune dysfunction) may benefit.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Cystic fibrosis (CF)</b><br>with severe lung disease or weight-for-length < 10 <sup>th</sup> percentile                                                    | Manifestations of severe disease include previous hospitalization for pulmonary exacerbation in the first year after birth or abnormalities on chest imaging that persist when stable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>American Indian or Alaska Native</b>                                                                                                                       | No additional requirement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

### Notes:

1. Qualifying criteria apply only to nirsevimab (Beyfortus®) administration in the 2<sup>nd</sup> RSV season, regardless of prior immunization or RSV infection. Clesrovimab (Enflonsia®) is not indicated in this age group. Nirsevimab is not recommended for any child who is aged 20 months and older.
2. An asterisk (\*) designates a new or expanded qualification criterion for the 2026-2027 RSV season.